All News

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, announces the signature of a Collaborative Services Agreement with ValiRx’s wholly owned subsidiary Inaphaea BioLabs Limited.   The agreement recognises the synergy between Inaphaea’s growing capabilities as a translational contract research organisation (tCRO®) providing in-vitro laboratory-based services and Physiomics’ in-silico capabilities for advanced statistical analyses, machine learning techniques, data handling...

Read More

Physiomics to present at AACR Annual Meeting   Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it is participating in the American Association for Cancer Research Annual Meeting 2023, being held on 14-19 April 2023 in Orlando, FL.   The Company will give an oral presentation entitled “Development and...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, would like to update the market on current trading and ongoing board restructuring and strategic initiatives.   Trading The Company continually monitors the lifescience environment in which it operates and, over the course of the year to date, the Company’s revenues have come under pressure at...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has signed an agreement with Beyond Blood Diagnostics Ltd (“Beyond Blood”) (https://beyondblood.co) to analyse data generated during testing of its diagnostic platform using Physiomics’ personalised dosing software.   Beyond Blood is a seed-stage spin out from Imperial College London,...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is hosting a free webinar on the Mathematical Modelling in the age of Project Optimus on 30th March 2023 from 3pm - 4pm (BST).   Who should attend? Anyone with an interest in getting approval for first in human and subsequent clinical studies. You might be an investor,...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending the AACR 2023 conference at the Orange County Convention Center, Orlando, FL, USA on 14-19 April 2023.   Physiomics Head of Business Development, Hayley Close, will be attending the conference. Companies interested in meeting with Physiomics should email Hayley directly at hclose@physiomics.co.uk.   Enquiries:   Physiomics plc                                                   Dr Jim Millen,...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending the BIO-Europe Spring digital conference on 28-30 March 2023.   Physiomics Head of Business Development, Hayley Close, will be attending the conference digitally. Companies interested in meeting with Physiomics should email Hayley directly at hclose@physiomics.co.uk.   Enquiries:   Physiomics plc                                                   Dr Jim Millen, CEO +44 (0)1865 784 980   Hybridan LLP (broker) Claire Louise...

Read More

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics (“Bicycle”).  The project relates to an undisclosed program and is expected to be completed in the Company’s current financial year.   Physiomics CEO, Dr Jim Millen, commented: “We are...

Read More

Cancer therapies are often associated with a ‘Goldilocks Window’ of optimal dosing: striking a balance where efficacy is maximised and toxicity is minimised. While mathematical modelling offers a powerful tool to inform optimal treatment approaches in cancer drug development, determining the right level of mechanistic detail to include in a model also requires careful consideration – hitting the right balance is both art and science.   You...

Read More